Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
2.96
0.00 (0.00%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.93 - 3.03
52 week 1.66 - 7.77
Open 2.99
Vol / Avg. 1.49M/3.05M
Mkt cap 349.36M
P/E     -
Div/yield     -
EPS -0.69
Shares 118.03M
Beta 0.86
Inst. own 30%
Aug 11, 2014
Q2 2014 Galena Biopharma Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 11, 2014
Q2 2014 Galena Biopharma Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 27, 2014
Galena Biopharma Inc Annual Shareholder Meeting
Jun 25, 2014
Galena Biopharma Inc at JMP Securities Healthcare Conference
Jun 24, 2014
Galena Biopharma Inc at ROTH Healthcare Corporate Access Day
Jun 5, 2014
Galena Biopharma Inc at Jefferies Global Healthcare Conference
May 29, 2014
Galena Biopharma Inc at Marcum MicroCap Conference
May 7, 2014
Galena Biopharma Inc at Deutsche Bank Healthcare Conference
May 6, 2014
Q1 2014 Galena Biopharma Inc Earnings Conference Call
May 6, 2014
Q1 2014 Galena Biopharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -116.70% -3083.15%
Operating margin -552.92% -1397.91%
EBITD margin - -1342.50%
Return on average assets -11.29% -107.27%
Return on average equity -38.83% -455.85%
Employees 60 -
CDP Score - -

Address

SUITE 270, 4640 SW MACADAM AVENUE
PORTLAND, OR 97239
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.

Officers and directors

Sanford J. Hillsberg J.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark J. Ahn Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Ryan M. Dunlap Chief Financial Officer, Vice President, Secretary
Age: 44
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. Chief Operating Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Brian L. Hamilton M.D. Ph.D. Executive Vice President and Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Irving M. Einhorn Director
Age: 72
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A. Kriegsman Independent Director
Age: 72
Bio & Compensation  - Reuters